PRX005

PRX005

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PRX005</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena/BMS</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT06268886</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Asset</td>
<td>Target</td>
</tr>
<tr>
<td class="label">PRX005 (BMS-986446)</td>
<td>Tau MTBR</td>
</tr>
<tr>
<td class="label">PRX012</td>
<td>Aβ</td>
</tr>
<tr>
<td class="label">PRX002</td>
<td>α-synuclein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PRX005</td>
</tr>

PRX005

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PRX005</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena/BMS</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT06268886</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05420546</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT05535756</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Asset</td>
<td>Target</td>
</tr>
<tr>
<td class="label">PRX005 (BMS-986446)</td>
<td>Tau MTBR</td>
</tr>
<tr>
<td class="label">PRX012</td>
<td>Aβ</td>
</tr>
<tr>
<td class="label">PRX002</td>
<td>α-synuclein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PRX005</td>
</tr>
<tr>
<td class="label">Target</td>
<td>MTBR</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Company</td>
<td>BMS/Prothena</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Monotherapy</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PRX005</td>
</tr>
<tr>
<td class="label">Company</td>
<td>BMS/Prothena</td>
</tr>
<tr>
<td class="label">Target</td>
<td>MTBR</td>
</tr>
<tr>
<td class="label">IgG Type</td>
<td>IgG1</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>0.2% plasma</td>
</tr>
</table>

PRX005 is a monoclonal antibody therapeutic targeting the microtubule-binding region (MTBR) of tau, developed by [Prothena](/companies/prothena) Biosciences in partnership with [Bristol Myers Squibb](/companies/bristol-myers-squibb) for the treatment of Alzheimer's disease and other tauopathies. This represents a next-generation approach to tau immunotherapy that addresses the limitations of earlier anti-tau antibody programs.

Overview

PRX005 is an IgG1 monoclonal antibody that specifically targets the MTBR of tau protein, particularly the region involved in tau-tau aggregation and fibril formation. This approach distinguishes PRX005 from earlier-generation anti-tau antibodies that targeted N-terminal epitopes, which failed to demonstrate clinical efficacy in Phase II trials[@lessons2024].

The development of PRX005 reflects a major paradigm shift in tau immunotherapy strategy:

• First-generation anti-tau antibodies targeted the N-terminal region of tau
• These failed in clinical trials (gosuranemab, tilavonemab, semorinemab)
• Second-generation approaches target the MTBR, which is the aggregation "seed" region

Tau Biology and Pathological Relevance

Tau Protein Structure

Tau is a microtubule-associated protein encoded by the MAPT gene on chromosome 17q21. It exists as six isoforms in the adult human brain, ranging from 352 to 441 amino acids. The protein comprises:

• N-terminal region (1-150 aa): Projection domain, projects away from microtubules
• Proline-rich region (151-244 aa): Multiple phosphorylation sites
• Microtubule-binding region (244-368 aa): 3-4 repeat sequences (R1-R4)
• C-terminal region (369-441 aa): Involved in aggregation

MTBR Structure and Function

The microtubule-binding region (MTBR) consists of:

• Repeat 1 (R1): VQIVYK (306-378)
• **Repeat 2 (R2): VQIINK (274-280)
• **Repeat 3 (R3): VQIVYK (306-378)
• **Repeat 4 (R4): VQIVYK (336-378)

Pathological Tau Species

In Alzheimer's disease and tauopathies, tau undergoes:

Mechanism of Action

Target Epitope

PRX005 binds to the MTBR region of tau, which contains the core aggregation-prone sequence (Q244-K280, V306-K378) responsible for fibril formation. By targeting this region, PRX005 aims to:

• Intercept tau aggregation at its nucleation site
• Clear both intracellular and extracellular pathological tau
• Potentially reduce tau seeding and propagation
• Prevent cell-to-cell transmission of pathology

Mode of Action

Why MTBR Targeting?

The rationale for MTBR targeting is based on several key observations:

• MTBR contains the core aggregation domain (VQIVYK hexapeptide)
• Pathological tau fragments enriched in MTBR are highly aggregation-prone
• N-terminal antibodies fail because they don't intercept the aggregation machinery
• MTBR antibodies can potentially enter cells and target intracellular tau

Clinical Development

Clinical Trial Status

Study Design

Phase I studies evaluate:

• Safety and tolerability
• Pharmacokinetics
• Target engagement (CSF tau reduction)
• Immunogenicity

Expected Outcomes

Based on mechanism and preclinical data:

• Dose-dependent reduction in CSF tau species
• Potential slowing of cognitive decline
• Generally well-tolerated safety profile

Comparison with Other Anti-Tau Antibodies

Anti-Tau Antibody Landscape

Key Differentiators

IgG Subclass Considerations

IgG1 advantages:

• Stronger Fc effector function
• Better microglial activation
• Enhanced intracellular clearance via TRIM21[@igg2024]
• More potent tau reduction in preclinical models

• Weaker Fc effector function
• Reduced clearance capability
• Less effective in clinical trials to date

Preclinical Data

In Vitro Studies

• PRX005 binds to recombinant human tau with high affinity (KD < 100 pM)
• Recognizes aggregated tau forms (PHFs, SFs) better than monomeric tau
• Neutralizes tau seeding activity in biosensor cells
• Does not bind to normal tau in mouse brain

In Vivo Studies

• Reduces insoluble tau in tau transgenic mouse models
• Improves behavioral deficits in tauopathy models
• Does not affect normal microtubule function
• Good brain penetration in non-human primates

Company Information

Developer: Prothena Biosciences Inc.

Prothena is a late-stage clinical biotechnology company headquartered in San Francisco, California. The company focuses on:

• Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS)
• Amyloid-related disorders (AL amyloidosis)
• Antibody discovery and development

• PRX005 (MTBR antibody, partnered with BMS)
• PRX012 (anti-Aβ antibody)
• PRX002 (α-synuclein antibody)

Partner: Bristol Myers Squibb

BMS acquired rights to PRX005 through a 2023 partnership agreement:

• BMS received exclusive worldwide rights
• Prothena retained certain co-development options
• Total deal value: $2.2 billion including upfront and milestones

Therapeutic Implications

Potential Benefits

Challenges and Limitations

Patient Selection

Ideal candidates for PRX005 may include:

• Early-stage Alzheimer's disease (MCI or mild dementia)
• Elevated tau on PET or CSF
• Amnestic phenotype
• Amyloid-positive status

Safety Considerations

Expected Adverse Events

• Infusion-related reactions
• Headache
• Amyloid-related imaging abnormalities (ARIA) - theoretical risk

Monitoring Requirements

• MRI before and during treatment
• Periodic cognitive assessment
• CSF biomarkers (optional)

Future Development Path

Registration Strategy

Based on current development:

• Phase II: Dose-finding in early AD
• Phase III: Pivotal trials in early AD
• Potential accelerated approval with biomarker endpoint

Combination Approaches

Rationale for combination:

• Anti-amyloid + anti-tau: Complementary mechanisms
• PRX005 + lecanemab: Both targeting pathological proteins
• Triple therapy: Add anti-neuroinflammatory

Competitive Landscape

The tau immunotherapy field has seen multiple failures, creating both challenge and opportunity:

Failed approaches:

• N-terminal antibodies (gosuranemab, tilavonemab, semorinemab)
• Failed to meet primary endpoints in Phase II

• MTBR antibodies (E2814, PRX005, bepranemab)
• ASOs (BIIB080 showing tau reduction)
• Small molecules (OGA inhibitors)

Clinical Development Status (2025)

Current Phase: Phase 2

PRX005 is currently in Phase 2 development for Alzheimer's disease[@prx0052024][@prx005phase2]:

Phase 1 Results Summary

Top-line Phase 1 results announced January 31, 2023 showed[@prx0052024]:

• CNS Penetration: Achieved 0.2% of plasma levels in CNS (meaningful exposure)
• Safety: All doses were safe and well-tolerated with no serious adverse events
• Dose-Proportional PK: Linear pharmacokinetics across dose levels tested
• Immunogenicity: No significant anti-drug antibody formation

Phase 2 Trial Design

The Phase 2 trial (NCT06268886) represents a significant advancement[@prx005phase2]:

• Enrollment: 475 participants with early AD (CDR 0.5 or 1)
• Duration: 72-week treatment course
• Dosing: Two dose levels vs placebo
• Primary Endpoint: CDR-SB change from baseline
• Sites: 199 sites across North America, Australia, Asia, and Europe
• Expected Completion: 2027

BMS Partnership Details

BMS acquired rights to PRX005 through a 2023 partnership agreement with Prothena:

• BMS received exclusive worldwide rights (July 2023)
• Prothena retained certain co-development options
• Total deal value: $2.2 billion including upfront and milestones
• BMS rebranded the asset as BMS-986446

Mechanism of Action Deep Dive

Why Targeting the MTBR Works

The rationale for MTBR targeting is based on several key observations[@mtbr2024][@tau2024]:

Tau Filament Structure Insights

Recent cryo-EM studies have revealed the atomic structure of tau filaments[@tauform2024]:

• MTBR forms the core of both PHFs and straight filaments
• The VQIVYK hexapeptide forms β-sheet rich structures
• Pathological tau adopts distinct conformations in different diseases
• Understanding these structures informs antibody design

TRIM21-Mediated Clearance

A key mechanism for MTBR-targeting antibodies is the TRIM21 pathway[@trim2021][@trim2024]:

IgG1 vs IgG4 Considerations

The choice of IgG1 subclass provides significant advantages[@igg2024]:

IgG1 advantages:

• Stronger Fc effector function (ADCC, CDC)
• Better microglial activation via FcγR
• Enhanced intracellular clearance via TRIM21
• More potent tau reduction in preclinical models

• Weaker Fc effector function
• Reduced clearance capability
• Less effective in clinical trials to date

Preclinical Data Deep Dive

In Vitro Studies

• PRX005 binds to recombinant human tau with high affinity (KD < 100 pM)
• Recognizes aggregated tau forms (PHFs, SFs) better than monomeric tau
• Neutralizes tau seeding activity in biosensor cells
• Does not bind to normal tau in mouse brain

In Vivo Studies

• Reduces insoluble tau in tau transgenic mouse models
• Improves behavioral deficits in tauopathy models
• Does not affect normal microtubule function
• Good brain penetration in non-human primates

Translation to Human

Key translation findings from preclinical to clinical:

• CNS penetration at 0.2% of plasma levels achieved in humans
• Dose-proportional PK supports monthly dosing
• Safety profile supports advancement to Phase 2

Company Information

Developer: Prothena Biosciences Inc.

Prothena is a late-stage clinical biotechnology company headquartered in San Francisco, California. The company focuses on:

• Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS)
• Amyloid-related disorders (AL amyloidosis)
• Antibody discovery and development

• PRX005 (MTBR antibody, partnered with BMS)
• PRX012 (anti-Aβ antibody)
• PRX002 (α-synuclein antibody)

Partner: Bristol Myers Squibb

BMS acquired rights to PRX005 through a 2023 partnership agreement:

• BMS received exclusive worldwide rights
• Prothena retained certain co-development options
• Total deal value: $2.2 billion including upfront and milestones
• BMS has rebranded PRX005 as BMS-986446

Prothena Pipeline (2025)

Prothena maintains a robust pipeline targeting neurodegenerative diseases[@prothenapipe][@bmsneuro]:

Therapeutic Implications

Potential Benefits

Challenges and Limitations

Patient Selection

Ideal candidates for PRX005 may include:

• Early-stage Alzheimer's disease (MCI or mild dementia)
• Elevated tau on PET or CSF
• Amnestic phenotype
• Amyloid-positive status

Safety Considerations

Expected Adverse Events

• Infusion-related reactions
• Headache
• Amyloid-related imaging abnormalities (ARIA) - theoretical risk

Monitoring Requirements

• MRI before and during treatment
• Periodic cognitive assessment
• CSF biomarkers (optional)

Future Development Path

Registration Strategy

Based on current development:

• Phase II: Dose-finding in early AD (2024-2027)
• Phase III: Pivotal trials in early AD (2027-2029)
• Potential accelerated approval with biomarker endpoint

Combination Approaches

Rationale for combination:

• Anti-amyloid + anti-tau: Complementary mechanisms
• PRX005 + lecanemab: Both targeting pathological proteins
• Triple therapy: Add anti-neuroinflammatory

BMS Strategic Context

BMS's neuroscience focus[@bmsneuro]:

• Expansion into Alzheimer's disease via partnership with Prothena
• Leveraging immunology expertise from oncology
• Strategic priority on disease-modifying therapies

Pharmacokinetics and Pharmacodynamics

PK Properties

The pharmacokinetic profile of PRX005 has been characterized in clinical studies:

• Half-life: Approximately 21-28 days, consistent with typical IgG1 antibodies
• Volume of distribution: Approximately 3-4 L, indicating distribution primarily in plasma
• Clearance: Low clearance supporting q4w or q8w dosing
• CNS penetration: 0.2% of plasma levels - meaningful for target engagement

Dose-Proportional Exposure

Phase 1 data demonstrated dose-proportional pharmacokinetics across the dose range tested:

• Linear exposure from low to high doses
• No accumulation with repeated dosing
• Steady state achieved by approximately 4-5 half-lives

Pharmacodynamic Effects

The pharmacodynamic effects include:

Exposure-Response Relationships

Population PK/PD modeling has informed:

• Efficacy: Higher exposure associated with greater target engagement
• Safety: No clear exposure-safety relationship for AEs
• Dosing: Supports q4w or q8w dosing intervals

Dosing Regimen

Current Dosing

Based on clinical trial data, the PRX005 dosing regimen is:

• Route: Intravenous infusion
• Dose: Multiple dose levels tested in Phase 1
• Frequency: Every 4 weeks (q4w)
• Infusion Time: Approximately 1-2 hours
• Premedication: Not typically required

Dose Selection Rationale

The doses selected for Phase 2 were based on:

• Target Engagement: Demonstrated CSF target engagement in Phase 1
• Safety Margin: Favorable safety profile across dose levels
• Practical Considerations: Balance of efficacy and manufacturing costs

Administration Guidelines

In clinical practice, PRX005 would be administered:

Patient Eligibility

Inclusion Criteria (Typical Phase 2)

Exclusion Criteria

Regulatory Considerations

Current Regulatory Status

PRX005 is currently in Phase 2 development with BMS as the sponsor:

• FDA: No Fast Track or Breakthrough designation (as of 2024)
• EMA: No PRIME designation (as of 2024)
• Development: Advancing through BMS partnership

Potential Registration Path

Given the current data, potential registration pathways include:

Challenges

• Clinical Endpoint: Demonstrating clinically meaningful benefit
• Patient Selection: Identifying biomarker-defined responders
• Comparator: No head-to-head comparison with other anti-tau antibodies

Competitive Analysis

Position in Tau Immunotherapy Landscape

PRX005 occupies a leading position among anti-tau antibodies in development:

Advantages of PRX005

Challenges and Risks

Future Development Plans

2025-2027 Milestones

• 2025-2026: Complete Phase 2 enrollment
• 2027: Phase 2 data readout
• 2028: Potential Phase 3 initiation

Potential Indications

Next-Generation Formulations

Future development may include:

• Subcutaneous formulation (improved convenience)
• Higher-affinity variants
• Bispecific antibodies (tau + amyloid)

Comparison with E2814 and Bepranemab

Key Differentiators

Competitive Positioning

PRX005 occupies a unique position:

• Only Phase 2 MTBR antibody in BMS portfolio
• Strong BMS partnership provides resources
• Differentiated from E2814 (Eisai) and bepranemab (UCB)
• BMS-986446 branding suggests integration into BMS pipeline

References